He specializes in Hemato-Oncology. His research focuses on drug resistance mechanisms in patients with cancer, chemotherapy and targeted therapy of lung cancer, predictive factors in lung cancer, and anemia management in patients with cancer. As a member of the IALT-Bio and LACE-Bio groups, he has been involved in the characterization of predictive factors with regard to adjuvant chemotherapy in patients with completely resected non-small cell Lung Cancer (NSCLC). He was also the worldwide Co-ordinating Investigator of the First-Line Erbitux in lung cancer (FLEX) trial.